Health Care

Insmed Inc. boosts Q2 2026 earnings, upgrades Brinsupri and TPIP revenue outlooks, citing strong sales, Phase 3 success, and FDA progress.

Smith & Nebhew plc launches a research centre with Imperial College London and the new FLOW FLEXTEND COBLATION Wand, advancing markerless surgical robotics and safer joint‑access procedures.

Coloplast Q3 2025/26: 6% revenue rise, 80% net profit boost amid currency and reimbursement headwinds—organic growth, strong core segments, and a robust future outlook.

Discover how AstraZeneca & Daiichi Sankyo’s Enhertu and Tagrisso+Orpathys combos reshape advanced NSCLC treatment, driving high ROI and value‑based payor models.

Explore Sandoz’s landmark collaboration with Shanghai Henlius Biotech, expanding its global biosimilar portfolio to 10 assets, boosting access and cost‑efficiency worldwide.

United Therapeutics’ recent Form 4 shows a strategic option exercise, trust‑based tax planning, and concentrated voting power—insights for investors and regulators.

Argenx’s Phase 3 success for efgartigimod (ALKIVIA) shows early, sustained benefit in autoimmune myositis, promising a high‑value, rare‑disease biologic despite manufacturing and pricing hurdles.

How AstraZeneca balances oncology trial results, payer demands, and ROI – why the Tagrisso‑Orpathys combo wins and volrustomig stops.

Lonza Group AG sees modest gains in early August, proving its biotech resilience amid Swiss market weakness and global geopolitical tensions.

Amgen Inc.: A stable biotech stock with rising earnings, a 4.1% dividend, and a diversified pipeline—ideal for income‑focused investors seeking long‑term growth.